Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
NCT02792413 · University Hospital, Montpellier · PHASE4 · terminated · last registry update 2023-08-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Modified study and new deposit in RECHMPL21\_0451” | – | Registry record, University Hospital, Montpellier |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-25Results posted on the registry: Thomas Nickolas, MD MS, Denosumab Inj 60 mg/ml (NCT03960554)
- 2024-07-25Also stopped (terminated): Thomas Nickolas, MD MS, Denosumab Inj 60 mg/ml (NCT03960554)
- 2024-07-19Results posted on the registry: Amgen, Denosumab (NCT03164928)
- 2024-07-17Phase 3 first posted: Xentria, Inc., MAB-22 + Prolia® (NCT06504966)
- 2024-07-03Also stopped (terminated): Mishaela Rubin, Denosumab 60 mg/ml [Prolia] (NCT03457818)
- 2024-05-20Results posted on the registry: Amgen, Denosumab (NCT03301857)
- 2024-05-16Results posted on the registry: Celltrion, CT-P41 + US-licensed Prolia (NCT04757376)
- 2024-05-08Results posted on the registry: Columbia University, Alendronate + Zoledronic Acid (NCT03396315)
- 2024-04-25Results posted on the registry: ETOP IBCSG Partners Foundation, Denosumab (NCT02129699)
- 2024-04-18Results posted on the registry: Teva Pharmaceuticals USA, TVB-009 + Prolia® (NCT04729621)
- 2024-04-09Also stopped (withdrawn): Taizhou Mabtech Pharmaceutical Co.,Ltd, Post-change CMAB807X + Pre-change CMAB807X (NCT05808673)
- 2024-03-18Phase 3 first posted: RenJi Hospital, Narlumosbart + Denosumab (NCT06314698)
- 2024-03-15Also stopped (terminated): James J. Peters Veterans Affairs Medical Center, Denosumab (Prolia) (NCT03029442)
- 2024-03-13Results posted on the registry: Roswell Park Cancer Institute, Denosumab (NCT03925532)
- 2024-02-28Also stopped (withdrawn): Amorphical Ltd., Amorphous calcium carbonate (NCT02864784)
- 2023-12-04Phase 3 first posted: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Denosumab Injection (NCT06154707)
- 2023-08-02Results posted on the registry: Massachusetts General Hospital, Teriparatide + Denosumab (NCT04026256)
- 2023-05-10Phase 3 first posted: Luye Pharma Group Ltd., Denosumab (NCT05853354)
- 2023-04-14Phase 3 first posted: Shanghai JMT-Bio Inc., Narlumosbart + Denosumab (NCT05813665)
- 2023-03-14Also stopped (withdrawn): Shenzhen People's Hospital, Denosumab Only Product (NCT05065164)
- 2023-03-08Results posted on the registry: Sandoz, GP2411 + EU-Prolia (EU-authorized Prolia®) (NCT03974100)
- 2023-02-15Results posted on the registry: University of Rochester, Denosumab (NCT03839459)
- 2022-12-28Results posted on the registry: Amgen, Denosumab (NCT02352753)
- 2022-12-28Also stopped (terminated): Amgen, Denosumab (NCT02352753)
- 2022-12-20Results posted on the registry: Amgen, Denosumab + Alternative osteoporosis medications (NCT03638128)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision